Eli Lilly Acquires Psychedelics Maker AtaiBeckley for $2.8 Billion
Eli Lilly announced the acquisition of psychedelic drugmaker AtaiBeckley for $2.8 billion, gaining access to experimental drugs based on DMT and MDMA being developed for mental health conditions like depression. The deal includes potential additional payments up to $1 billion if development milestones are met.
Topics: mental health treatments pharmaceuticals psychedelics